AMRI and Proteros Biostructures GmbH Announce Strategic Alliance
News Jul 20, 2011
Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI’s existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.
Proteros’ expertise in structural biology services combined with AMRI’s expansive discovery and development capabilities provides biotechnology and pharmaceutical companies throughout the world access to a portfolio of contract services from two companies known for their high level of expertise, dedication to quality and impressive track record of success.
Torsten Neuefeind, Proteros CEO stated, “Proteros is pleased to announce this partnership and looks forward to the new opportunities we can provide to the life science community as a result of this alliance with AMRI.”
“We are excited about this new relationship that expands the depth and level of service we can offer to customers around the globe looking for integrated solutions from one point of service and contact,” said Thomas E. D’Ambra, Ph.D., AMRI Chairman, President and CEO.
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE